Mohamed Genead, M.D., M.Sc.

Equibles does not estimate personal net worth.

Get an email with a short summary when Ocugen, Inc. publishes a filing, an earnings call transcript or a press release.

About Mohamed Genead, M.D., M.Sc.

Ocugen, Inc. reported in an 8-K filed May 14, 2026 that Mohamed Genead, M.D., M.Sc. was appointed Acting/Interim Chief Medical Officer, effective May 8, 2026. Mohamed Genead, M.D., M.Sc. has spoken on 2 earnings calls across 1 company, most recently for Ocugen, Inc. on November 4, 2026. Ocugen, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ocugen, Inc. includes Shankar Musunuri (CEO), Quan Anh Vu (CFO), Ramesh Ramachandran (CFO and Chief Accounting Officer) and 6 others.

“Effective May 8, 2026, the Company appointed Mohamed Genead, M.D., M.Sc., as Acting/Interim Chief Medical Officer.”

Ocugen, Inc. Form 8-K, filed May 14, 2026 · Read the filing

Mohamed Genead, M.D., M.Sc. on recent calls

“So, as we subside in the protocol, this interim analysis was pre-subsified in the original protocol we discussed with the agency, and it was a part of our adaptive design to look at any adjustment need during, you know, the trial, conduction, and the DMC was assembled, as you're aware, and they recommended to continue…”

Other, Ocugen, Inc. Third Quarter 2026 Financial Results and Recent Business Highlights · November 4, 2026

“Regarding Armada III, which is our global phase II trial for GA, which we just got the approval from FDA just recently to be initiated this quarter.”

Other, Ocugen, Inc. Q2 FY2026 Earnings Call · August 6, 2026